Business Context and Reporting Period
Company: Modular Medical, Inc. (MODD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 31, 2024
Business Overview: A pre-revenue medical device company developing the MODD1, a two-part patch insulin pump. The company received FDA clearance for the MODD1 in September 2024 and aims to commence initial shipments in the first half of fiscal 2026.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2024 | Nine Months Ended Dec 31, 2024 | Balance Sheet (Dec 31, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(4,804) | $(13,897) | N/A |
| Operating Expenses | $4,854 | $14,070 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $6,986 |
| Total Assets | N/A | N/A | $12,149 |
| Total Liabilities | N/A | N/A | $1,887 |
| Stockholders' Equity | N/A | N/A | $10,262 |
| Accumulated Deficit | N/A | N/A | $(79,826) |
Cash Flow (Nine Months Ended Dec 31, 2024):
- Net cash used in operating activities: $(11,410)
- Net cash used in investing activities: $(1,545)
- Net cash provided by financing activities: $10,709
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by $415,000 (7.9%) for the three months ended Dec 31, 2024, compared to the same period in 2023. This was driven by a $430,000 decrease in General and Administrative (G&A) expenses, partially offset by a slight increase in R&D expenses.
- Net Loss: Net loss improved to $(4.8M) for the quarter from $(5.3M) in the prior year quarter. For the nine-month period, net loss increased to $(13.9M) from $(13.2M).
- Capital Structure: The company completed a firm commitment underwritten offering in November 2024, issuing approximately 5.45 million shares for net proceeds of $7.3 million. Additionally, the company raised $2.1 million through at-the-market (ATM) sales and $1.3 million from warrant exercises during the nine-month period.
- Headcount: Full-time R&D employee headcount increased to 44 as of December 31, 2024, from 36 in the prior year.
Outlook, Risks, and Management Commentary
- Going Concern: The company has incurred operating losses since inception and has no revenue. Management states that these conditions raise substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Future operations depend on raising additional capital.
- Commercialization: Following FDA clearance in September 2024, the company is actively working to commercialize the MODD1 product, with initial shipments targeted for the first half of fiscal 2026.
- Future Expenses: Management expects R&D and G&A expenses to increase for the remainder of fiscal 2025 to support commercialization activities and new product development.
- Risks: Key risks include the inability to secure additional financing, which could force the curtailment of R&D and commercialization efforts. The company also faces standard risks associated with pre-revenue medical device companies, including regulatory hurdles and market competition.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.0 million cash balance against the projected burn rate of approximately $11.4 million over nine months to assess the timeline for the next capital raise.
- Commercialization Timeline: Monitor progress toward the stated goal of initial MODD1 shipments in the first half of fiscal 2026 (April–September 2025).
- Dilution Risk: Review the impact of outstanding warrants (11.2 million shares) and options (4.6 million shares) on future share count and potential dilution.
- Capital Expenditures: Confirm the status of the $1.1 million in outstanding purchase orders for machinery and equipment required for manufacturing.